ViroPharma: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:ViroPharma}} | |||
[[File:ViroPharma_Corporate_Logo.png|thumb|right|ViroPharma Corporate Logo]] | |||
'''ViroPharma''' was a biopharmaceutical company that focused on the development and commercialization of products for the treatment of diseases caused by viral infections. The company was known for its work in the field of [[infectious diseases]], particularly in developing therapies for [[hepatitis C]] and [[hereditary angioedema]]. | |||
==History== | |||
ViroPharma was founded in 1994 and was headquartered in [[Exton, Pennsylvania]]. The company initially focused on developing antiviral drugs, with a particular emphasis on [[hepatitis C virus]] (HCV) and [[cytomegalovirus]] (CMV) infections. Over the years, ViroPharma expanded its research and development efforts to include other areas of unmet medical need. | |||
In 2004, ViroPharma acquired the rights to [[Vancocin]], an antibiotic used to treat [[Clostridium difficile]] infections, which became a significant part of its product portfolio. This acquisition marked a strategic shift for the company, allowing it to diversify its offerings beyond antiviral therapies. | |||
==Products== | |||
ViroPharma's product portfolio included several key therapies: | |||
* '''Vancocin''': An oral antibiotic used to treat [[Clostridium difficile]]-associated diarrhea. Vancocin was one of the company's most successful products, contributing significantly to its revenue. | |||
* '''Cinryze''': A C1 esterase inhibitor used for the treatment of [[hereditary angioedema]] (HAE). Cinryze was approved by the [[Food and Drug Administration]] (FDA) in 2008 and became a cornerstone of ViroPharma's offerings. | |||
== | ==Acquisition== | ||
In 2014, ViroPharma was acquired by [[Shire plc]], a global biopharmaceutical company. The acquisition was valued at approximately $4.2 billion and was part of Shire's strategy to expand its rare disease portfolio. Following the acquisition, ViroPharma's products, including Cinryze, were integrated into Shire's operations. | |||
==Research and Development== | |||
ViroPharma was actively involved in research and development, focusing on innovative therapies for viral infections and rare diseases. The company invested in clinical trials and collaborations with academic institutions to advance its pipeline of potential treatments. | |||
== | ==Legacy== | ||
ViroPharma's contributions to the field of biopharmaceuticals, particularly in the treatment of rare diseases and infectious diseases, have had a lasting impact. The company's focus on unmet medical needs and its successful development of therapies like Cinryze have been recognized as significant achievements in the industry. | |||
* [[ | ==Related pages== | ||
* [[ | * [[Biopharmaceutical]] | ||
* [[ | * [[Hereditary angioedema]] | ||
* [[Clostridium difficile]] | |||
* [[Shire plc]] | |||
[[Category:Biopharmaceutical companies]] | |||
[[Category:Defunct companies of the United States]] | |||
[[Category:Companies established in 1994]] | |||
[[Category:Companies disestablished in 2014]] | |||
[[Category: | |||
[[Category: | |||
[[Category: | |||
Latest revision as of 12:09, 15 February 2025
ViroPharma was a biopharmaceutical company that focused on the development and commercialization of products for the treatment of diseases caused by viral infections. The company was known for its work in the field of infectious diseases, particularly in developing therapies for hepatitis C and hereditary angioedema.
History[edit]
ViroPharma was founded in 1994 and was headquartered in Exton, Pennsylvania. The company initially focused on developing antiviral drugs, with a particular emphasis on hepatitis C virus (HCV) and cytomegalovirus (CMV) infections. Over the years, ViroPharma expanded its research and development efforts to include other areas of unmet medical need.
In 2004, ViroPharma acquired the rights to Vancocin, an antibiotic used to treat Clostridium difficile infections, which became a significant part of its product portfolio. This acquisition marked a strategic shift for the company, allowing it to diversify its offerings beyond antiviral therapies.
Products[edit]
ViroPharma's product portfolio included several key therapies:
- Vancocin: An oral antibiotic used to treat Clostridium difficile-associated diarrhea. Vancocin was one of the company's most successful products, contributing significantly to its revenue.
- Cinryze: A C1 esterase inhibitor used for the treatment of hereditary angioedema (HAE). Cinryze was approved by the Food and Drug Administration (FDA) in 2008 and became a cornerstone of ViroPharma's offerings.
Acquisition[edit]
In 2014, ViroPharma was acquired by Shire plc, a global biopharmaceutical company. The acquisition was valued at approximately $4.2 billion and was part of Shire's strategy to expand its rare disease portfolio. Following the acquisition, ViroPharma's products, including Cinryze, were integrated into Shire's operations.
Research and Development[edit]
ViroPharma was actively involved in research and development, focusing on innovative therapies for viral infections and rare diseases. The company invested in clinical trials and collaborations with academic institutions to advance its pipeline of potential treatments.
Legacy[edit]
ViroPharma's contributions to the field of biopharmaceuticals, particularly in the treatment of rare diseases and infectious diseases, have had a lasting impact. The company's focus on unmet medical needs and its successful development of therapies like Cinryze have been recognized as significant achievements in the industry.
